Xcout Intel
OncoZenge
OncoZenge is a pharmaceutical development company that creates targeted treatments for oral pain, primarily focusing on oral mucositis caused by cancer radiotherapy and chemotherapy. Its lead product candidate, BupiZenge, is a bupivacaine-based lozenge designed to provide safe, local, and non-opioid pain relief for patients.
Subscribe to see OncoZenge’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
OncoZenge at a glance
OncoZenge is a health care company headquartered in Sweden. Xcout tracks 6 named people at OncoZenge, including Stian Kildal (CEO).
OncoZenge leadership
- Stian KildalCEO
- Michael OwensChief Financial Officer (CFO)
- Marie-Louise FjällskogBoard member, Chief Medical Officer
- Daniel EhrenstråhleChairman of the board
- Marie MooresBoard member
- Paul MurtaghBoard member
OncoZenge competitors
A few of OncoZenge's closest competitors — see the full list of competitors and alternatives →
Sprint Bioscience is a pharmaceutical company that develops innovative preclinical drug candidates for cancer treatments. Utilizing a fragment-based drug discovery method, the company creates and out-licenses its drug programs to global pharmaceutical partners.
Oral Biolife is an innovative biotech company that develops first-in-class piezoelectric therapies converting mechanical force into bone regeneration. Headquartered in Bethlehem, Pennsylvania, the firm is transforming periodontal treatments with products such as Ambrilux Dental Gel.
Brise Pharmaceuticals Co., Ltd. is a pioneering biopharmaceutical company specializing in the discovery and development of innovative treatments for chronic pain. The company is led by expert research professionals and focuses on advancing clinical therapeutics. It is headquartered in Shanghai, China.
Spago Nanomedical is a clinical-stage pharmaceutical company that develops precision nanomedicine products for the diagnosis and treatment of cancer and other severe diseases. Its pipeline includes Tumorad, a targeted radionuclide therapy for various cancers, and SpagoPix, a polymeric contrast agent designed to improve the precision of MRI diagnostics.
FluoGuide is a biotechnology company that develops products for precision cancer surgery to improve patient outcomes. Its lead product, FG001, illuminates cancerous tissue during procedures to help surgeons perform more precise operations and reduce cancer recurrence.
Enzymatica develops health solutions and barrier technology products, such as the ColdZyme mouth spray, designed to support the body's defense against viruses and micro-organisms. The company serves consumers looking to prevent or alleviate common cold symptoms and respiratory infections.
Get OncoZenge's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on OncoZenge in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access